NMNoriomi Miyao

Noriomi Miyao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Noriomi Miyao has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 April 2015
      • Vol. 61  (4) , 135-9

    [Prognostic factors and efficacy of molecular targeted therapy for metastatic clear cell renal cell carcinoma].

    by Ryuta Inoue, Hiroshi Kitamura, Tetsuya Shindo, Masahiro Yanase, Atsushi Takahashi, Noriomi Miyao, Naoki Ito, Hiroshi Hotta, Takaoki Hirose, Keisuke Taguchi, et al.

    We retrospectively reviewed the medical records of patients with metastatic clear cell renal cell carcinoma who received molecular targeted therapy between 2005 and 2011. Cancer-specific survival was analyzed using the Kaplan-Meier method. Predictors of cancer-specific survival were analyzed using the Cox regression hazards model. A total of 89 patients, consisting of 50 first line patients and 39 patients receiving prior cytokine were included in the analysis. The two-year cancer-specific survival rate of the firstlinegroup was 60.2% and that of theprior cytokinethe rapy group was 62.1%. In univariateanalysis, Karnofsky performance status (KPS)<80%, time from diagnosis to treatment less than one year, bone metastasis and C-reactive protein (CRP)>1.3 mg/dl in were statistically significant prognostic factors (p<0.05). In multivariate analysis, time from diagnosis to treatment less than one year (HR 2.46, 95%CI 1.11-5.82, p=0.025) and CRP (HR 4.92, 95%CI 2.23-11.3, p<0.001) were independent prognostic factors. Time from diagnosis to treatment less than one year and CRP were independent prognostic factors in patients who received molecular targeted therapy.

  • Construction of Predictive Models for Cancer-specific Survival of Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: Results from a Multicenter Retrospective Study

    by Naotaka Nishiyama, Hiroshi Kitamura, Hiroshi Hotta, Atsushi Takahashi, Masahiro Yanase, Naoki Itoh, Hitoshi Tachiki, Noriomi Miyao, Masanori Matsukawa, Yasuharu Kunishima, et al.

    The aims of this study were to clarify the prognostic factors and to validate the bacillus Calmette-Guérin failure classification advocated by Nieder et al. in patients with non-muscle-invasive bladder cancer who had intravesical recurrence after bacillus Calmette-Guérin therapy. Data from 402 patients who received intravesical bacillus Calmette-Guérin therapy between January 1990 and November 2011 were collected from 10 institutes. Among these patients, 187 with bacillus Calmette-Guérin failure were analyzed for this study. Twenty-nine patients (15.5%) were diagnosed with progression at the first recurrence after bacillus Calmette-Guérin therapy. Eighteen (62.1%) of them died of bladder cancer. A total of 158 patients were diagnosed with non-muscle-invasive bladder cancer at the first recurrence after bacillus Calmette-Guérin therapy. Of them, 23 (14.6%) underwent radical cystectomy. No patients who underwent radical cystectomy died of bladder cancer during the follow-up. On multivariate analysis of the 135 patients with bladder preservation, the independent prognostic factors for cancer-specific survival were age (≥70 [P = 0.002]), tumor size (≥3 cm [P = 0.015]) and the Nieder classification (bacillus Calmette-Guérin refractory [P < 0.001]). In a subgroup analysis, the estimated 5-year cancer-specific survival rates in the groups with no positive, one positive and two to three positive factors were 100, 93.4 and 56.8%, respectively (P < 0.001). Patients with stage progression at the first recurrence after bacillus Calmette-Guérin therapy had poor prognoses. Three prognostic factors for predicting survival were identified and used to categorize patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin into three risk groups based on the number of prognostic factors in each one.


  • Open Access

    Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension: a multi-institutional retrospective study in Japan

    by Masanori Hirono, Mikio Kobayashi, Tomoyasu Tsushima, Wataru Obara, Nobuo Shinohara, Keiichi Ito, Masatoshi Eto, Tatsuya Takayama, Yasuhisa Fujii, Masaharu Nishikido, et al.

    Background: Although the percentage of patients with renal cell carcinoma (RCC) extending into venous systems is unexpectedly high, the prognostic impact and independency of venous tumor thrombus-related factors on overall survival (OS) remain controversial. Furthermore, the prognostic impact of various clinicopathologic factors including tumor thrombus-related factors on OS may change with elapsed years after the intervention and also with follow-up duration of participants. The aim of the study is to explore independent and universal predictive preoperative and intraoperative clinicopathologic factors on OS in patients with RCC extending into venous systems using subgroup analysis in terms of restricted follow-up duration and yearly-based survivors. Methods: Between 1980 and 2009, 292 patients diagnosed with RCC with venous tumor thrombus were retrospectively registered for this study. The prognostic impacts of various clinicopathologic and surgical treatment factors including levels of venous thrombus, venous wall invasion status and likelihood of aggressive cytoreductive operation, were investigated using Kaplan-Meier method and following multivariate Cox proportional hazards model for all patients and those still alive at 1, 2, and 3 years of follow-up. To investigate the impact of follow-up duration on the statistical analyses, multivariate logistic regression analyses were used to explore prognostic factors using restricted data until 1, 2, and 3 years of follow-up. Results: The median follow-up duration was 40.4 months. The 5-year OS was 47.6%. Several independent predictive factors were identified in each subgroup analysis in terms of yearly-based survival and restricted follow-up duration. The presence of tumor thrombus invading to venous wall was independently related to OS in the full-range follow-up data and in survivors at 2 and 3 years of follow-up. Using restricted follow-up data until 1, 2, and 3 years of follow-up, many independent predictive factors changed with follow-up duration, but surgical category could be universal and independent predictive factors. Conclusion: The most universal factors affecting improvement both in short-term and long-term survivals could be cytoreductive surgery and absence of venous wall invasion. It may mean that feasible aggressive cytoreductive operation following more reliable preoperative imaging for predicting venous wall invasion status would improve OS for patients with RCC extending into venous systems.


    • 1 July 2012
      • Vol. 58  (7) , 315-8

    [Clinical study of laparoscopic adrenalectomy in Sapporo Medical University].

    by Satoshi Takahashi, Naoya Masumori, Hiroshi Kitamura, Naoki Itoh, Atsushi Takahashi, Masanori Matsukawa, Yasuharu Kunishima, Ryuichi Kato, Noriomi Miyao, Taiji Tsukamoto

    The purpose of this retrospective study was to identify the surgical outcome and complications of laparoscopic adrenalectomy at Sapporo Medical University Hospital. One hundred fifty-six patients underwent laparoscopic adrenalectomy due to primary aldosteronism in 64 (41.0%), Cushing's syndrome in 34 (21.8%), endocrinological non-functioning tumors in 27 (17.3%), pheochromocytoma in 23 (14.7%) and others. The median time of the surgery was 140 minutes (range 70 to 345) and the median volume of blood loss was 10 ml (0-1,200). From 1999, the operation time was around the median time of this study and from 2006, it was commonly below the median time of this study. There were 4 cases (2.6%) with complications; however, no severe cases occurred. In conclusion, laparoscopic adrenalectomy in our hospital has been performed safely as a standard treatment.

  • Late Recurrence of Renal Cell Carcinoma: Retrospective and Collaborative Study of the Japanese Society of Renal Cancer

    by Noriomi Miyao, Seiji Naito, Seiichiro Ozono, Nobuo Shinohara, Naoya Masumori, Tatsuo Igarashi, Masahiro Nakao, Tomoyasu Tsushima, Yutaka Senga, Shigeo Horie, et al.


  • Open Access

    The prevalence of renal cell carcinoma: A nation-wide survey in Japan in 1997

    by Ken Marumo, Yoshiaki Satomi, Noriomi Miyao, Michihiko Hasegawa, Yoshihiko Tomita, Tatsuo Igarashi, Tetsuro Onishi, Hayakazu Nakazawa, Momokuni Fukuda, Seiichiro Ozono, et al.


  • A CLINICAL STUDY OF RADICAL PROSTATECTOMY

    by Hiroshi Hotta, Noriomi Miyao, Naoya Masumori, Atsushi Takahashi, Keito Sasamura, Hiroshi Kitamura, Taiji Tsukamoto, Keiji Takatsuka, Hideki Adachi, Yoshio Takagi, et al.

    (Background) The objective of this study is to evaluate the efficacy of radical prostatectomy for patients with organ-confined prostate cancer.(Methods) From 1990 to 1994, a total of 50 patients with prostate cancer underwent radical retropubic prostatectomy.(Results) Eleven patients were in stage A2, 34 in stage B and 5 in stage C according to clinical stage. Extended disease was observed pathologically in 45%, and 59% of patients in clinical stages A2 and B, respectively. Preoperative serum PSA levels were closely correlated with pathological extension of the disease. The disease-free rates for organ-confined disease, extended disease without lymph node metastasis and stage D1 disease were 75% (3 years), 82% (2 years) and 80% (3 years), respectively. Four patients had rectal injuries, and three of these underwent temporary colostomy diversion. Two patients had bladder neck contracture and received internal urethrotomy. Urinary incontinence improved in 60% of patients during the first 6 post-operative and in 90% of patients within 12 post-operative months. Urinary incontinence tended to improve earlier in patients with nerve-sparing than in those without it. The erectile capacity in nerve-sparing patients recovered good.(Conclusion) Our results indicate that radical prostatectomy is a safe and temporarily satisfactory treatment for the patient with organ-confined prostate cancer.

  • Open Access

    Dose Finding Study of Sparfloxacin in Single-Dose Therapy for Female Acute Uncomplicated Cystitis

    by Takaoki Hirose, Yoshiaki Kumamoto, Akibumi Yokoo, Tsugio Umehara, Masabumi Miyake, Keiji Takatsuka, Takashi Sato, Shin-Ichi Miyamoto, Noriaki Tanaka, Noriomi Miyao, et al.

    Sparfloxacin (SPFX) is a new quinolone compound with a long half-life of 16 hours and a potent antibacterial activity (MIC90:≤0.025μg/ml against Escherichia colt), suggesting that the agent can be effectively used in single-dose therapy for acute uncomplicated cystitis in female patients. To find the optimum dose, the present dose-finding study was conducted. A dose of either 100 mg or 200mg of SPFX was selected by the double-blind method, and was administered only once (single dose therapy). Theclinicalefficacywasjudged on day 3, 7 and 14 after administration. On day 3, of the 49 pts. in the 100 mg-group, the efficacy icacy rate was 95.9%(excellent rate: 79.6%), and of the 42 pts. in the 200 mg-group, it was 100%(excellent rate: 88.1%). On day 7, of 38 pts. in the 100 mg-group, it was 94.7%(excellent rate: 78.9%), and of 28 pts. in the 200 mg-group, it was 100%(excellent rate: 92.9%). On day 14, of 27 pts. in the 100 mg-group, it was 92.6%(excellent rate: 66.7%), and of 26 in the 200 mg-group, it was 96.2%(excellent rate: 84.6%). Recurrence was observed in 4.8%(1/21) in the 200 mg-group. Therefore, there was no significant difference in the efficacy rate between the two groups, but the rate of excellent responses was higher in the 200 mg-group. Otherwise, the efficacy was estimated to be insufficient in 3 pts. and recurrent in 1 pt. they were examined the findings of detailed urological intractableness. Among 2 pts. in whom the external genitalia and urethra were closely examined, a urethral caruncle was noted in 1 pt. The results of our study indicate that 200 mg of SPFX is recommended as a single dose therapy for acute uncomplicated cystitis in females.


  • INFLUENTIAL FACTORS ON RECURRENCE OF RENAL CELL CARCINOMA

    by Atsushi Takahashi, Yoshiaki Kumamoto, Taiji Tsukamoto, Noriomi Miyao, Noriyuki Otani, Masahiro Yanase, Naoya Masumori

    In order to clarify factors affecting recurrence, we reviewed 115 renal cell carcinoma patients without distant metastasis at diagnosis (Mo) treated from January 1975 to March 1990 at Sapporo Medical College Hospital. Of these 115 patients, recurrence (metastasis) was found in 23 (20.0%). The non-recurrence rate was 70.6% after the 5-year and 56.5% after the 10-year follow up. In 22 out of 23 patients, recurrence appeared within 3 years following surgery. Multivariate analysis by Cox's proportional hazard model revealed that lymph node metastasis was the most significant factor for recurrence in the 115 patients followed by stage of the primary tumor and pre-operative acute phase reactant (fever, ESR and α2-globulin) in this order.When the analysis was performed in the 88 patients who was in less advanced stage (pNopVo-1a), pre-operative acute phase reactant (fever, ESR and α2-globulin) was identified as the only significant factor affecting recurrence. This result suggests that pre-operative acute phase reactant is the most important risk factor for recurrence in this group of patients.


  • CLINICAL EFFICACY OF MODIFIED M-VAC CHEMOTHERAPY FOR ADVANCED UROTHELIAL CARCINOMA AND INFLUENCE OF SQUAMOUS CELL CARCINOMA-ASSOCIATED ANTIGEN ON EFFICACY OF THE CHEMOTHERAPY

    by Noriyuki Otani, Yoshiaki Kumamoto, Taiji Tsukamoto, Noriomi Miyao, Hideo Iwabe, Masahiro Yanase, Atsushi Takahashi, Naoya Masumori

    The efficacy of modified M-VAC chemotherapy was evaluated in twenty-two patients with advanced urothelial carcinoma (18 cases of transitional cell carcinoma, 3 of transitional cell associated with squamous cell carcinoma and 1 of squamous cell carcinoma). Among the 22 patients, 14 underwent two or more courses of modified M-VAC chemotherapy and had lesions suitable for the evaluation. Three of the 14 patients achieved complete response and 6 partial response, resulting in a 64.3% response rate. With regard to the direct effect according to the site of the lesion, the response rate was 75% for the urinary bladder, 100% for lung, 100% for subcutaneous tissues, and 75% for lymph nodes metastasis, whereas the chemotherapy was ineffective for metastasis in the bone and muscle. With this neoadjuvant chemotherapy the primary tumor of the urinary bladder was downstaged from T2 to T0 in one patient who showed complete response. In 4 of 5 patients achieving partial response, the primary tumors were downstaged from T2 to T1. Of 9 patients given this chemotherapy for metastatic lesions, 2 achieved complete response and are alive, whereas all 3 without response died of cancer within the 1 year following the chemotherapy. Since most of the cases associated with the squamous cells carcinoma component showed no response to the therapy, it seems that the level of serum squamous cell carcinoma-associated antigen may be helpful for predicting the efficacy of modified M-VAC chemotherapy. Side effects related to this chemotherapy and their incidences were as follows: leukocytopenia (less than 1, 000/mm3) 18.2%, thrombocytopenia (less than 100, 000/mm3) 27.2%, nausea and vomiting 100%, hair loss 90.9% and renal dysfunction (Ccr 50l/day or less) 13.6%. No serious side effects were found in our series.